25 April 2016 - CMS will convene a panel of the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) on 27 April 2016.

The purpose of this meeting is to obtain the MEDCAC's recommendations regarding the definition of treatment resistant depression (TRD) in clinical research as well as advise CMS on the use of the definition of TRD in the context of coverage with evidence development and treatment outcomes.

MEDCAC panels do not make coverage determinations, but may advise CMS how to use evidence as the basis for any future coverage decisions.

For more details, go to: https://www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=71&bc=AgAIAAAAAAAAAA%3d%3d&